(Q46913592)

26 December 2017

meta-analysis

0 references

title

An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. (English)

1 reference

26 December 2017

1 reference

Rosario B Hidalgo

1

1 reference

26 December 2017

Larry A Tupler

series ordinal

2

1 reference

26 December 2017

Jonathan R T Davidson

series ordinal

3

1 reference

26 December 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

26 December 2017

Journal of Psychopharmacology

published in

1 reference

26 December 2017

volume

21

1 reference

26 December 2017

page(s)

864-872

1 reference

26 December 2017

issue

8

1 reference

26 December 2017

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

Efficacy of sertraline in a 12-week trial for generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

A placebo-controlled study of Kava kava in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

The assessment of anxiety states by rating

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

Generalized anxiety disorder. An important clinical concern

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

Efficacy and Safety of Hydroxyzine in the Treatment of Generalized Anxiety Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

Pregabalin in generalized anxiety disorder: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

Efficacy of kava extract for treating anxiety: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

Placebo response in studies of major depression: variable, substantial, and growing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

Phenomenology and course of generalised anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107076996

21 January 2018

Identifiers

DOI

10.1177/0269881107076996

1 reference

26 December 2017

release_2g76qufaljgy5n3cttscppjbya

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2g76qufaljgy5n3cttscppjbya

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

17984162

1 reference

26 December 2017